stockrow
Saturday 7 November 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million.
- EPS
- +10.5%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
1.73
0.07
+4.22%
Follow BDTX
Alert me
Black Diamond Therapeutics, Inc. (BDTX) P/E ratio
Black Diamond Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 32.4× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 6.2× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 19.4× | — |
Against its own ten years
Low 0.0×
High 32.4×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDTX Black Diamond Therapeutics, Inc. | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| VANI Vivani Medical, Inc. compare | n/m |
| NMRA Neumora Therapeutics, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| VXRT VAXART, INC. compare | 2.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)